Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 13/20 | 0.66 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.66 |
| ▸ | IL6 | P05231 | 4/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4129263 | 0.93 | TLR7 (0.63) | TLR7NUDT1IL6 | |
| SCHEMBL4129752 | 0.90 | TLR7 (0.59) | TLR7NUDT1IL6 | |
| SCHEMBL4134428 | 0.88 | TLR7 (0.73) | TLR7NUDT1IL6 | |
| SCHEMBL1146487 | 0.88 | TLR7 (0.75) | TLR7NUDT1IL6 | |
| SCHEMBL4133858 | 0.88 | TLR7 (0.58) | TLR7NUDT1IL6 | |
| SCHEMBL1146403 | 0.88 | TLR7 (0.71) | TLR7NUDT1IL6 | |
| SCHEMBL1146177 | 0.86 | TLR7 (0.85) | TLR7NUDT1IL6 | |
| SCHEMBL24247649 | 0.85 | TLR7 (0.66) | TLR7NUDT1IL6 | |
| SCHEMBL29395647 | 0.85 | TLR7 (0.66) | TLR7NUDT1IL6 | |
| SCHEMBL1146594 | 0.85 | TLR7 (0.67) | TLR7NUDT1IL6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105212-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) | 2009-04-23 | — | — | US | claimed |
| EP-1939201-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-02 | — | — | EP | claimed |
| US-11851428-B2 | Activator of TREK (TWIK RElated K+channels) channels | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-12-26 | — | — | US | disclosed |
| US-11572374-B2 | N-cyano-7-azanorbornane derivatives and uses thereof | AMGEN INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20220363694-A1 | N-CYANO-7-AZANORBORNANE DERIVATIVES AND USES THEREOF | AMGEN INC. (US) | 2022-11-17 | — | — | US | disclosed |
| US-20210347773-A1 | ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-11-11 | — | — | US | disclosed |
| US-11046683-B2 | Activator of TREK (TWIK RElated K+ channels) channels | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-29 | — | — | US | disclosed |
| US-20190322662-A1 | ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-10-24 | — | — | US | disclosed |
| US-8853218-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2014-10-07 | — | — | US | disclosed |
| WO-2012037108-A1 | AMINOQUINOLINE DERIVATIVES AS ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | WO | disclosed |
| US-20090192160-A1 | COMPOUNDS | GLAXO GROUP LIMITED | 2009-07-30 | — | — | US | disclosed |
| US-20090105212-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) | 2009-04-23 | — | — | US | disclosed |
| US-20090105212-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) | 2009-04-23 | — | — | US | disclosed |
| US-20090105212-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) | 2009-04-23 | — | — | US | disclosed |
| EP-1939201-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
| US-20070060566-A1 | Benzazepine derivatives as histamine h3 antagonists | GLAXO GROUP LIMITED (GB) | 2007-03-15 | — | — | US | disclosed |
| EP-1753861-A2 | FRUCTOSEAMINE 3 KINASE AND THE FORMATION OF COLLAGEN AND ELASTIN | Dynamis Therapeutics, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005079463-A2 | FRUCTOSEAMINE 3 KINASE AND THE FORMATION OF COLLAGEN AND ELASTIN | DYNAMIS THERAPEUTICS, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11851428-B2 | Activator of TREK (TWIK RElated K+channels) channels | KCNJ11, KCNJ1, KCNJ8 | TLR7 1750/4885NUDT1 568/4885IL6 3308/4885 |
| US-20190322662-A1 | ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS | KCNJ11, KCNJ1, KCNJ8 | TLR7 1750/4885NUDT1 568/4885IL6 3308/4885 |
| US-11046683-B2 | Activator of TREK (TWIK RElated K+ channels) channels | KCNJ11, KCNJ1, KCNJ8 | TLR7 1750/4885NUDT1 568/4885IL6 3308/4885 |
| US-11572374-B2 | N-cyano-7-azanorbornane derivatives and uses thereof | CYP3A7, CYP51A1, NT5C3B | TLR7 828/4885NUDT1 206/4885IL6 1033/4885 |
| US-20090192160-A1 | COMPOUNDS | GPR68, GPR88, GPBAR1 | TLR7 454/4885NUDT1 2677/4885IL6 2447/4885 |
| US-20070060566-A1 | Benzazepine derivatives as histamine h3 antagonists | HRH3, HRH4, HRH1 | TLR7 3645/4885NUDT1 1492/4885IL6 3293/4885 |
| US-20210347773-A1 | ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS | KCNJ11, KCNJ1, KCNJ8 | TLR7 1750/4885NUDT1 568/4885IL6 3308/4885 |
| US-20220363694-A1 | N-CYANO-7-AZANORBORNANE DERIVATIVES AND USES THEREOF | CYP3A7, CYP51A1, NT5C3B | TLR7 828/4885NUDT1 206/4885IL6 1033/4885 |
| US-20090105212-A1 | NOVEL ADENINE COMPOUND | XDH, ADORA1, NUDT1 | TLR7 396/4885NUDT1 3/4885IL6 3519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.